August 26, 2016 (PPI-OT) / PRNewswire / Asianet-Pakistan: Following is the text of press release issued by HemispherxBiopharma Quote HemispherxBiopharma, Inc. (NYSE:HEB) (the “Company” or “Hemispherx”), announced that it has received approval of its New Drug Application (NDA) from AdministracionNacional de Medicamentos, Alimentos y TecnologiaMedica (ANMAT) for commercial sale of rintatolimod (U.S. tradename: Ampligen®) in the…